The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer

The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer

Abstract Combination chemotherapy, either modified FOLFIRINOX (mFFX) or gemcitabine–nabpaclitaxel, are used in the treatment of most patients with advanced pancreatic ductal adenocarcinoma (PDAC), yet robust biomarkers of outcome are currently lacking to guide regimen selection. Here, we tested GATA...

Full description

Bibliographic Details
Main Authors: Kai Duan, Gun-Ho Jang, Robert C. Grant, Julie M. Wilson, Faiyaz Notta, Grainne M. O’Kane, Jennifer J. Knox, Steven Gallinger, Sandra Fischer
Format: Article
Language:English
Published: Nature Portfolio 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-94544-3

Internet

https://doi.org/10.1038/s41598-021-94544-3

Similar Items